Carbidopa and Levodopa Enteral Suspension and Ibritumomab Intravenous
Determining the interaction of Carbidopa and Levodopa Enteral Suspension and Ibritumomab Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: carbidopa / levodopa
Brand name: Parcopa, Rytary, Sinemet, Sinemet CR, Duopa
Synonyms: Carbidopa and levodopa, Carbidopa and Levodopa
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Ibritumomab, Ibritumomab Tiuxetan
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Carbidopa and Levodopa Enteral Suspension-Ibritumomab Tiuxetan
- Carbidopa and Levodopa Enteral Suspension-Ibrutinib
- Carbidopa and Levodopa Enteral Suspension-Ibrutinib Capsules
- Carbidopa and Levodopa Enteral Suspension-Ibrutinib Tablets
- Carbidopa and Levodopa Enteral Suspension-Ibu
- Carbidopa and Levodopa Enteral Suspension-IBU Tablets
- Ibritumomab Intravenous-Carbidopa and Levodopa Extended-Release Capsules
- Ibritumomab Intravenous-Carbidopa and Levodopa Extended-Release Tablets
- Ibritumomab Intravenous-Carbidopa and Levodopa ODT
- Ibritumomab Intravenous-Carbidopa and Levodopa Orally Disintegrating Tablets
- Ibritumomab Intravenous-Carbidopa and levodopa Route Not Applicable
- Ibritumomab Intravenous-Carbidopa and Levodopa Tablets